Table 3 Comparison of CMg-identified genotypic resistance with phenotypic culture results and the impact on guideline-recommended beta-lactam antibiotic treatment

S1

K. aerogenes

No

–

–

Y

Meropenem

S10

K. pneumoniae

No

–

–

Y

Co-amoxiclav

S11

K. pneumoniae

No

–

–

Y

Co-amoxiclav

S20

S. aureus

Erythromycin

Erythromycin

erm

Y

Co-amoxiclav

S21

E. cloacae

No

No

–

Y

Meropenem

S31

K. pneumoniae

ESBL

Co-trimoxazole

ESBL

Co-trimoxazole

bla_TEM,

bla_SHV

bla_CTX-M,

sul

Y

Y

Meropenem

S34

K. pneumoniae

No

ESBL

bla_TEM, bla_SHV

N

Meropenem^b

S35

A. baumannii

ESBL

–

N

Meropenem

S36

S. aureus

Erythromycin

Trimethoprim

Erythromycin

Trimethoprim

erm

dfrG

Y

Co-amoxiclav

S37

P. mirabilis

No

Amoxicillin

Trimethoprim

bla_OXA

dfrA

N

N

Meropenem

M. morganni

Co-trimoxazole

Fosfomycin

Nitrofurantoin

Co-trimoxazole

–

–

dfrA

Y

N

N

S39

C. koseri

Amoxicillin

Amoxicillin

bla_CKO

Y

Co-amoxiclav

S44

S. marcescens

No

–

–

Y

Meropenem

S49

K. pneumoniae

ESBL

ESBL

bla_TEM

Y

Meropenem

S51

S. aureus

Erythromycin

Erythromycin

erm

Y

Co-amoxiclav

C. koseri

Amoxicillin

Amoxicillin

bla_CKO

Y

S52

K. aerogenes

Gentamicin

–

–

N

Meropenem

S56

P. mirabilis

Amoxicillin

Co-trimoxazole

Amoxicillin

–

bla_TEM

–

Y

N

Co-amoxiclav

S59

K. pneumoniae

ESBL

Co-trimoxazole

ESBL

Co-trimoxazole

bla_TEM,

bla_SHV,

sul

Y

Y

Meropenem

S61

P. mirabilis

No

–

–

Y

Co-amoxiclav

K. pneumoniae

No

–

–

Y

S62

K. aerogenes

ESBL

–

–

N

Meropenem

S63

K. pneumoniae

ESBL

ESBL

bla_SHV

Y

Meropenem